REAl-world outcomes in CHronic lymphocytic leukemia patients receiving acalabrutinib in Romania - REACH
Study identifier:D8220R00055
ClinicalTrials.gov identifier:NCT06170671
EudraCT identifier:N/A
CTIS identifier:N/A
Recruitment Complete
Official Title
Observational, secondary data collection study to describe acalabrutinib treatment outcomes in chronic lymphocytic leukemia patients in real-life setting in Romania
Medical condition
Chronic Lymphocytic Leukemia
Phase
N/A
Healthy volunteers
No
Study drug
Non interventional study
Sex
All
Actual Enrollment
250
Study type
Observational
Age
18 Years - 130 Years
Date
Study Start Date: 13 Dec 2023
Estimated Primary Completion Date: 30 Sept 2028
Estimated Study Completion Date: 30 Sept 2028
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Sept 2025 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Cohort 1 December 2023 - collecting data retrospectively from patients routinely initiated on acalabrutinib between January - December 2023 | Drug: Non interventional study CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection Other Name: Not applicable |
| Cohort 2 December 2024-collecting data retrospectively from patients routinely initated on acalabrutinib between January - December 2024 | Drug: Non interventional study CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection Other Name: Not applicable |
